tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Syntara Begins Phase 1a/b Trial for Anti-Scarring Drug SNT-9465

Story Highlights
  • Syntara Limited starts Phase 1a/b trial for SNT-9465 targeting hypertrophic scars.
  • Trial results could lead to FDA application, making SNT-9465 a pioneering treatment for skin scarring.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Syntara Begins Phase 1a/b Trial for Anti-Scarring Drug SNT-9465

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Pharmaxis Ltd ( (AU:SNT) ) just unveiled an update.

Syntara Limited has commenced dosing the first participant in its Phase 1a/b clinical trial for SNT-9465, a next-generation topical anti-fibrotic drug aimed at treating hypertrophic scars. This trial will assess the drug’s safety and tolerability, with results expected in the first half of 2026. The trial’s outcomes could lead to an FDA Investigational New Drug application, potentially establishing SNT-9465 as the first approved pharmacological treatment for skin scarring, addressing a significant unmet need in the market.

The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.12 price target. To see the full list of analyst forecasts on Pharmaxis Ltd stock, see the AU:SNT Stock Forecast page.

More about Pharmaxis Ltd

Syntara Limited is a clinical-stage drug development company focused on creating first-in-class drugs. The company is actively engaged in multiple clinical trials targeting high-value commercial opportunities, particularly in the treatment of skin scarring.

Average Trading Volume: 9,888,378

Technical Sentiment Signal: Sell

Current Market Cap: A$91.05M

Find detailed analytics on SNT stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1